Core Insights - Johnson & Johnson announced long-term data from the QUASAR study showing that TREMFYA® (guselkumab) maintains clinical and endoscopic remission in ulcerative colitis patients over three years, with over 80% of patients in clinical remission and more than 50% in endoscopic remission at Week 140 [1][2]. Group 1: Clinical Efficacy - At Week 140, 80.8% of patients treated with TREMFYA® were in clinical remission, while 53.6% achieved endoscopic remission [1]. - 78.6% of patients experienced histo-endoscopic mucosal improvement (HEMI), indicating significant intestinal healing [1]. - Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140, demonstrating sustained efficacy [1]. Group 2: Study Retention and Safety - Approximately 89% of eligible study participants completed treatment through Week 140, indicating high retention rates [1]. - No new safety concerns were reported during the study, reinforcing the long-term safety profile of TREMFYA® [1][2]. Group 3: Mechanism and Approval - TREMFYA® is the first and only approved dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, targeting immune-mediated diseases [1][2]. - The drug has received FDA and European Commission approval for treating both moderately to severely active Crohn's disease and ulcerative colitis [1][2]. Group 4: Additional Research and Commitment - Johnson & Johnson presented 30 abstracts at the European Crohn's and Colitis Organisation (ECCO) 2026 conference, highlighting ongoing research and commitment to inflammatory bowel disease treatments [1]. - Two other abstracts from Johnson & Johnson were recognized as Top 10 oral abstracts, showcasing the company's dedication to advancing treatment options [1].

Core Insights - TREMFYA® (guselkumab) has received FDA approval for the treatment of adults with moderately to severely active Crohn's disease, marking it as the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options [2][3] - The approval builds on previous indications for TREMFYA® in moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active ulcerative colitis, highlighting Johnson & Johnson's commitment to addressing chronic immune-mediated diseases [3][8] - Clinical trials, including the GRAVITI and GALAXI studies, demonstrated TREMFYA®'s superiority over STELARA® in achieving clinical remission and endoscopic response, with significant efficacy results [2][6][7] Company Overview - Johnson & Johnson is a leader in healthcare innovation, focusing on developing treatments for chronic immune-mediated diseases, including inflammatory bowel disease [2][39] - The company maintains exclusive worldwide marketing rights to TREMFYA® and is committed to supporting patient access through programs like TREMFYA® withMe [2][10] Industry Context - Crohn's disease affects approximately three million Americans, and there is a significant need for effective treatment options as many patients continue to experience debilitating symptoms despite existing therapies [2][8] - The approval of TREMFYA® represents a significant advancement in the treatment landscape for Crohn's disease, providing a new option that allows for self-administration and flexibility in treatment regimens [2][3][6]